Novonesis Invests €600M in Indian Enzyme Production, Boosting Bio-Ingredient Supply
Novonesis's €600 million investment in a new Indian enzyme facility, operational by 2030, strengthens global biosolution supply chains and positions India as a key biomanufacturing hub, impacting ingredient costs and availability for various industries.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Copenhagen, Denmark — 07 September 2026
Novonesis, a prominent biosolutions provider, has committed €600 million to establish a new enzyme manufacturing facility in Patalganga, Maharashtra, India. This significant investment aims to bolster Novonesis's global production network and enhance supply capabilities across India, the Middle East, Africa, and South Asia. The facility, expected to be fully operational by 2030, will produce enzymes for diverse applications, including food and beverages, biofuels, and household care, addressing rising industry demand for sustainable bio-based solutions and improved supply chain resilience.
Krishna Mohan Puvvada, Regional President for the Middle East, India & Africa at Novonesis, highlighted India's strategic position as a biomanufacturing hub, citing the nation's talent pool and supportive government initiatives like the BioE3 framework. This framework is designed to accelerate innovation and manufacturing of bio-based products, including essential enzymes. The investment underscores a broader industry trend towards decentralising production and leveraging regional strengths to mitigate supply chain vulnerabilities and reduce lead times, a critical factor for manufacturers navigating volatile raw material markets.
The expansion aligns with increasing pressure on manufacturers to adopt sustainable production processes. Novonesis states the Patalganga facility will incorporate water recycling and energy-efficient technologies to minimise resource consumption and reduce Scope 1 and 2 emissions. This move anticipates evolving consumer expectations for cleaner labels and sustainable sourcing, alongside regulatory momentum towards healthier living and reduced environmental impact. The ability to supply biosolutions that facilitate less waste and more efficient resource utilisation directly addresses key operational challenges for food processors and supplement formulators.
What this means for United Kingdom
UK supplement manufacturers should anticipate potential shifts in enzyme ingredient procurement strategies as Novonesis's Indian facility comes online by 2030. Increased supply availability from a diversified network could stabilise pricing and reduce lead times for key enzyme ingredients used in digestive health, sports nutrition, and functional food supplements. Brands focused on sustainability claims will find opportunities to source ingredients from a facility committed to Scope 1 and 2 emission reductions and water efficiency. Procurement teams should monitor supplier diversification and contract terms to capitalise on improved global supply chain resilience, potentially impacting cost of goods by Q1 2031.
"India also has the talent and skillsets needed to make this facility a reality, and deliver on our ambitions toward a bio-based economy," stated Krishna Mohan Puvvada of Novonesis, as reported by Food Ingredients First.
The investment reflects a growing industry focus on leveraging biotechnology to meet both production efficiency and sustainability goals. For supplement manufacturers, the broader availability of bio-based ingredients can enable reformulation opportunities for cleaner labels and enhanced functional claims, addressing sophisticated consumer demands for both efficacy and environmental responsibility. Novonesis will showcase relevant solutions at Fi Asia Indonesia 2026, indicating their commitment to regional market engagement.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.